-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Dow Jones·05/26/2026 11:00:00

Please log in to view news